Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Living with pulmonary hypertension: quality not just quantity

R. Condliffe
European Respiratory Journal 2011 38: 512-513; DOI: 10.1183/09031936.00027911
R. Condliffe
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: robin.condliffe@sth.nhs.uk
  • Article
  • Info & Metrics
  • PDF
Loading

Pulmonary arterial hypertension (PAH) is a rare disease characterised by progressive right heart failure and premature death with a median survival prior to the availability of effective treatments of <3 yrs [1, 2]. There has been significant progress in its management over the last two decades with the introduction of three classes of targeted therapies: prostanoids, endothelin-1 receptor antagonists (ERAs) and phosphodiesterase-5 inhibitors [3]. A number of randomised controlled trials (RCTs) have demonstrated the efficacy of these drugs in terms of exercise capacity, functional class and pulmonary haemodynamics [4–11]. Observational studies have suggested improved survival when compared with historical series [12–14] and a recent meta-analysis of RCTs has confirmed a significant survival benefit associated with targeted therapies [15]. These therapies, however, have potentially significant side-effects related to continuous intravenous or subcutaneous infusion, frequent nebulisation or the requirement for close biochemical monitoring. In this context, the demonstration of therapy-related improvements in health-related quality of life (HRQoL), and not just in relatively modest improvements in exercise capacity or pulmonary haemodynamics, is of great importance to patients, prescribers and providers alike.

The majority of RCTs in PAH have assessed HRQoL as a secondary outcome using either generic tools, such as the Short Form (SF)-36 health survey, or measures validated in cardiac disease, such as the Minnesota Living with Heart Failure Questionnaire (LHFQ) [16, 17]. The results have been inconsistent, with some studies demonstrating significant improvement in HRQoL in at least some domains [4, 6, 8, 9, 18, 19] while others have failed to demonstrate any significant effect on HRQoL at all [11, 20]. There have been relatively few studies specifically assessing HRQoL in PAH. Initial studies examined the nature and level of HRQoL impairment and observed significant impairment across multiple domains [21, 22]. Interestingly, HRQoL correlated with exercise capacity as measured by the 6-min walk distance (6MWD) and World Health Organization (WHO) functional class, but not pulmonary haemodynamics [22]. Although Taichman et al. [22] demonstrated impairment in HRQoL as assessed by the St George’s Respiratory Questionnaire (SGRQ; a pulmonary-specific tool) and SF-36, no direct comparison between these generic and pulmonary-specific tools was made. Subsequent studies assessed the change in HRQoL over time. Cenedese et al. [23] found the LHFQ to be moderately responsive to therapy and also predictive of event-free survival. The generic SF-36 has been compared with the cardiac-specific LHFQ in two previous studies, which once again demonstrated significant associations with changes in 6MWD and WHO functional class [24, 25]. In recognition of the need for a PAH-specific HRQoL assessment tool, McKenna et al. [26] and Gomberg-Maitland et al. [27] constructed the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), which has since been validated in a US cohort. The effect of bosentan, an ERA, on HRQoL was subsequently assessed in 55 patients; interestingly, the CAMPHOR score was found to be more sensitive to changes in HRQoL than the WHO functional class [28].

With the availability of generic, pulmonary-specific, cardiac-specific and PAH-specific HRQoL assessment measures, it is therefore high time that the most appropriate and responsive tool for use in future PAH trials is identified. The study by Chen et al. [29] in the current issue of the European Respiratory Journal goes some way towards this. In their study, they enrolled 128 consecutive PAH patients and prospectively compared three main assessment tools: the generic SF-36, the cardiac-specific LHFQ and the pulmonary-specific 20-item Airways Questionnaire (AQ-20), which had previously been developed by the SGRQ investigators as a similar but less onerous test [30]. They also compared the PAH-specific CAMPHOR score, although due to the timing of the study, this was only available for a minority of the whole cohort. Some important findings were observed. First, the LHFQ correlated strongly with the AQ-20 while both tools showed convergent validity in correlating with the SF-36. Secondly, scores for the LHFQ and AQ-20 were non-normally distributed with evidence of a “ceiling effect” (i.e. a proportion of patients had the best possible score at baseline). Thirdly, although the three main HRQoL tools discriminated well between patients based on WHO functional class and Borg Dyspnoea Index (BDI), the LHFQ and AQ-20 failed to discriminate between patients in the lower two quartiles of 6MWD, a possible “floor effect”. In addition, although all three main HRQoL measures were responsive to change in WHO functional class, 6MWD and BDI, over time, they were less sensitive to worsening than to improvement. Overall, the AQ-20 was the least responsive test while the LHFQ was the most responsive. Also, there was some suggestion that the LHFQ was superior to the AQ-20 in predicting both the physical component score of the SF-36 and the CAMPHOR score in the small subset of patients with CAMPHOR results at follow-up. Finally, estimates of clinically meaningful change for each tool were derived using two separate methods; these should be of significant value when interpreting the clinical significance of changes in HRQoL in future trials.

So how much further forward do these findings take us? PAH is a condition affecting the interface between the pulmonary and cardiovascular systems. The present study suggests that in a cohort of PAH patients typical of those enrolled in RCTs, both cardiac- and pulmonary-specific tools are indeed valid methods of assessing HRQoL. There is also evidence to suggest that the cardiac-specific LHFQ is the superior of the two system-specific measures. The case for superiority of system-specific over more generic HRQoL measures is, however, not yet proven. Two important avenues of research into PAH-associated HRQoL follow on from this point. First, to more confidently identify the optimal HRQoL measure for use in PAH trials, the SF-36 and LHFQ measures must now be compared with the disease-specific CAMPHOR in a large prospective cohort. Secondly, the optimal HRQoL measure for subgroups of PAH in which comorbidities may also negatively impact on HRQoL, such as systemic sclerosis-associated PAH (in which HRQoL is significantly lower than even in idiopathic PAH [22]), needs specific investigation.

Footnotes

  • Statement of Interest

    A statement of interest for R. Condliffe can be found at www.erj.ersjournals.com/site/misc/statements.xhtml

  • ©ERS 2011

REFERENCES

  1. ↵
    1. D’Alonzo GE,
    2. Barst RJ,
    3. Ayres SM,
    4. et al
    . Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991; 115: 343–349.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Simonneau G,
    2. Robbins IM,
    3. Beghetti M,
    4. et al
    . Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S43–S54.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Galie N,
    2. Hoeper MM,
    3. Humbert M,
    4. et al
    . Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219–1263.
    OpenUrlFREE Full Text
  4. ↵
    1. Barst RJ,
    2. Rubin LJ,
    3. Long WA,
    4. et al
    . A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296–302.
    OpenUrlCrossRefPubMedWeb of Science
    1. Rubin LJ,
    2. Badesch DB,
    3. Barst RJ,
    4. et al
    . Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896–903.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Simonneau G,
    2. Barst RJ,
    3. Galie N,
    4. et al
    . Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800–804.
    OpenUrlCrossRefPubMedWeb of Science
    1. Olschewski H,
    2. Simonneau G,
    3. Galie N,
    4. et al
    . Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322–329.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Galie N,
    2. Ghofrani HA,
    3. Torbicki A,
    4. et al
    . Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148–2157.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Galie N,
    2. Badesch D,
    3. Oudiz R,
    4. et al
    . Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 529–535.
    OpenUrlCrossRefPubMedWeb of Science
    1. Galie N,
    2. Brundage BH,
    3. Ghofrani HA,
    4. et al
    . Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894–2903.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Barst RJ,
    2. Langleben D,
    3. Frost A,
    4. et al
    . Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441–447.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Sitbon O,
    2. Humbert M,
    3. Nunes H,
    4. et al
    . Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780–788.
    OpenUrlCrossRefPubMedWeb of Science
    1. Dimopoulos K,
    2. Inuzuka R,
    3. Goletto S,
    4. et al
    . Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010; 121: 20–25.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Condliffe R,
    2. Kiely DG,
    3. Peacock AJ,
    4. et al
    . Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151–157.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Galie N,
    2. Manes A,
    3. Negro L,
    4. et al
    . A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009; 30: 394–403.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Ware JE,
    2. Sherbourne CD
    . The MOS 36-item short-form health survey (SF-36): conceptual framework and item selection. Med Care 1992; 30: 473–483.
    OpenUrlCrossRefPubMedWeb of Science
  13. ↵
    1. Rector TS,
    2. Kubo SH,
    3. Cohn JN
    . Patients' self-assessment of their congestive heart failure: part 2. Content, reliability and validity of a new measure: the Minnesota Living with Heart Failure Questionnaire. Heart Failure 1987; 1: 198–209.
    OpenUrl
  14. ↵
    1. Pepke-Zaba J,
    2. Gilbert C,
    3. Collings L,
    4. et al
    . Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. Chest 2008; 133: 183–189.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Pepke-Zaba J,
    2. Beardsworth A,
    3. Chan M,
    4. et al
    . Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension. Curr Med Res Opin 2009; 25: 2479–2485.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Barst RJ,
    2. McGoon M,
    3. McLaughlin V,
    4. et al
    . Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119–2125.
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    1. Shafazand S,
    2. Goldstein MK,
    3. Doyle RL,
    4. et al
    . Health-related quality of life in patients with pulmonary arterial hypertension. Chest 2004; 126: 1452–1459.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Taichman DB,
    2. Shin J,
    3. Hud L,
    4. et al
    . Health-related quality of life in patients with pulmonary arterial hypertension. Respir Res 2005; 6: 92.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Cenedese E,
    2. Speich R,
    3. Dorschner L,
    4. et al
    . Measurement of quality of life in pulmonary hypertension and its significance. Eur Respir J 2006; 28: 808–815.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Chua R,
    2. Keogh AM,
    3. Byth K,
    4. et al
    . Comparison and validation of three measures of quality of life in patients with pulmonary hypertension. Intern Med J 2006; 36: 705–710.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    1. Zlupko M,
    2. Harhay MO,
    3. Gallop R,
    4. et al
    . Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension. Respir Med 2008; 102: 1431–1438.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    1. McKenna SP,
    2. Doughty N,
    3. Meads DM,
    4. et al
    . The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006; 15: 103–115.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Gomberg-Maitland M,
    2. Thenappan T,
    3. Rizvi K,
    4. et al
    . United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Transplant 2008; 27: 124–130.
    OpenUrlCrossRefPubMedWeb of Science
  24. ↵
    1. Meads DM,
    2. McKenna SP,
    3. Doughty N,
    4. et al
    . The responsiveness and validity of the CAMPHOR Utility Index. Eur Respir J 2008; 32: 1513–1519.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Chen H,
    2. De Marco T,
    3. Kobashigawa EA,
    4. et al
    . Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension. Eur Respir J 2011; 38: 608–616.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Quirk FH,
    2. Jones PW
    . Repeatability of two new short airways questionnaires. Thorax 1994; 49: 1075P.
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 38 Issue 3 Table of Contents
European Respiratory Journal: 38 (3)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Living with pulmonary hypertension: quality not just quantity
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Living with pulmonary hypertension: quality not just quantity
R. Condliffe
European Respiratory Journal Sep 2011, 38 (3) 512-513; DOI: 10.1183/09031936.00027911

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Living with pulmonary hypertension: quality not just quantity
R. Condliffe
European Respiratory Journal Sep 2011, 38 (3) 512-513; DOI: 10.1183/09031936.00027911
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • REFERENCES
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • SARS-CoV-2-induced senescence as a potential therapeutic target
  • Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe Covid-19?
  • Commemorating World Tuberculosis Day 2022
Show more Editorial

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society